优立新与西力欣序贯疗法治疗下呼吸道感染的对照研究

The Sequential Treament of Lower Respiratory Tract Infections: a Comparative Study of Unasyn and Zincef

本试验旨在评价优立新序贯疗法治疗下呼吸道感染的临床疗效和安全性。西力欣作为对照。入选病例６１例，其中试验组（优立新）３１例，对照组（西力欣）３０例。给药方法采用静脉注射随后口服给药的序贯疗法：静脉注射优立新３～１２ｇ／天，连续 ３～７天，继之口服舒他西林３７５ｍｇ～７５０ｍｇ，每天２次，连续５～７天；静脉注射西力欣３～６ｇ／天，继之口服新菌灵２５０ｇ～５００ｇ，每天 ２次，疗程相同。结果试验组和对照组的临床有效率分别为８０．６％（２５／３１）和９０％（２７／３０）。６１例患者共分离出致病菌４１株。治疗结束后两组的细菌清除率分别为 ８２．１４％（２３／２８）和 ６９．２３％（９／１３），毒副作用反应发生率分别为 ６．４５％和３． ３３％。上述结果经统计学处理无显著性差异。无病者因毒副作用而退出试验。

In order to evaluate the clinical efficacy and safety of Unasyn by sequential method in lower respiratory tract infection, sixty-one patients were enrolled in the study, of them 31 cases were in Unasyn group and the other(30) cases were in Zincef group for control. The mode of drug administration was intravenous injection followed by P. O. (Sequential meth- od): intravenous injection of Unasyn 3 ~ 12g/day, consecutively for 3 ~ 7 days, followed by Sultamicilin 375~750 mg, bid, for 5~7 days; Intravenous injection of Zincef 3~6 g/day, followed by Zinnat 250~500mg, bid, and the course of treatment was the same as above. The results showed that the clinical effective rates in the experimental group and the control were 80. 6 % and 90. 0 %, respectively. Totally 41 stains of pathogens were isolated from the 61 patients. After treatment the clearance rates of bacteria in the two groups were 82. 1% and 69. 2 %, respectively. The incidences of the side effects during the treatment course were 6. 45 % and 3. 33 %, respectively. No statistically significant difference in the above data occurred between the two groups, and none of the patients withdrew from me experiment.